EP2694463B8 - Behandlung von tumoren im zentralnervensystem mit coenzym q10 - Google Patents
Behandlung von tumoren im zentralnervensystem mit coenzym q10 Download PDFInfo
- Publication number
- EP2694463B8 EP2694463B8 EP12767439.8A EP12767439A EP2694463B8 EP 2694463 B8 EP2694463 B8 EP 2694463B8 EP 12767439 A EP12767439 A EP 12767439A EP 2694463 B8 EP2694463 B8 EP 2694463B8
- Authority
- EP
- European Patent Office
- Prior art keywords
- coenzyme
- nervous system
- central nervous
- system tumors
- treating central
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471659P | 2011-04-04 | 2011-04-04 | |
| PCT/US2012/032178 WO2012138765A1 (en) | 2011-04-04 | 2012-04-04 | Methods of treating central nervous system tumors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| EP2694463A1 EP2694463A1 (de) | 2014-02-12 |
| EP2694463A4 EP2694463A4 (de) | 2014-10-29 |
| EP2694463B1 EP2694463B1 (de) | 2019-09-04 |
| EP2694463B8 true EP2694463B8 (de) | 2019-10-09 |
Family
ID=46969535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP12767439.8A Active EP2694463B8 (de) | 2011-04-04 | 2012-04-04 | Behandlung von tumoren im zentralnervensystem mit coenzym q10 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20120269867A1 (de) |
| EP (1) | EP2694463B8 (de) |
| JP (3) | JP6092844B2 (de) |
| KR (1) | KR101933732B1 (de) |
| CN (1) | CN103608323B (de) |
| AU (2) | AU2012240222B2 (de) |
| CA (1) | CA2832324C (de) |
| ES (1) | ES2762451T3 (de) |
| WO (1) | WO2012138765A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX345044B (es) | 2009-05-11 | 2017-01-16 | Berg Llc | Métodos para el diagnóstico de trastornos oncológicos usando cambiadores epimetabólicos, moléculas intracelulares multidimensionales o influenciadores ambientales. |
| EP2694463B8 (de) | 2011-04-04 | 2019-10-09 | Berg LLC | Behandlung von tumoren im zentralnervensystem mit coenzym q10 |
| EP2983654A4 (de) | 2013-04-08 | 2016-11-30 | Berg Llc | Behandlung von krebs mit coenzym-q10-kombinationstherapien |
| CA2919432A1 (en) * | 2013-07-30 | 2015-02-05 | Benemilk Oy | Feed for lactating ruminants |
| KR102370843B1 (ko) | 2013-09-04 | 2022-03-04 | 버그 엘엘씨 | 코엔자임 q10의 연속주입에 의한 암치료 방법 |
| CN104173835A (zh) * | 2014-09-03 | 2014-12-03 | 四川金堂海纳生物医药技术研究所 | 一种治疗淋巴管瘤的内服药物及其制备方法 |
| MX2021006835A (es) | 2018-12-14 | 2021-07-02 | Colgate Palmolive Co | Composiciones para el cuidado personal basadas en emulsiones sin silicona y metodos para estas. |
| US11883514B2 (en) * | 2019-11-01 | 2024-01-30 | Colgate-Palmolive Company | Stable low pH personal care compositions and methods for the same |
| US20210322339A1 (en) * | 2019-11-20 | 2021-10-21 | Berg Llc | Combination therapy of coenzyme q10 and radiation for treatment of glioma |
Family Cites Families (391)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4525350A (en) | 1975-02-20 | 1985-06-25 | The New England Institute, Inc. | Methods of stimulating host defense system with coenzymes Q4 to Q.sub.1 |
| JPS5775916A (en) | 1980-10-29 | 1982-05-12 | Nippon Chemiphar Co Ltd | Coenzyme q pharmaceutical and its preparation |
| JPS58113127A (ja) | 1981-12-28 | 1983-07-05 | Ajinomoto Co Inc | ユビデカレノン含有水性液 |
| IT1157269B (it) | 1982-03-19 | 1987-02-11 | Seuref Ag | Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica |
| JPS58201711A (ja) | 1982-05-19 | 1983-11-24 | Eisai Co Ltd | ユビデカレノン含有リポソ−ム被覆体 |
| US4515736A (en) | 1983-05-12 | 1985-05-07 | The Regents Of The University Of California | Method for encapsulating materials into liposomes |
| US4833128A (en) | 1984-12-28 | 1989-05-23 | Neil Solomon | Dietary supplement |
| US4824669A (en) | 1985-04-11 | 1989-04-25 | Board Of Regents, The University Of Texas System | Formulations of coenzyme Q10 for intravenous use |
| US4895727A (en) | 1985-05-03 | 1990-01-23 | Chemex Pharmaceuticals, Inc. | Pharmaceutical vehicles for exhancing penetration and retention in the skin |
| JPS62123113A (ja) | 1985-11-22 | 1987-06-04 | Green Cross Corp:The | ユビデカレノン含有脂肪乳剤 |
| US4843071A (en) | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
| US5651991A (en) | 1987-10-28 | 1997-07-29 | Nippon Shinyaku Co. Ltd. | Drug carriers |
| JP2600726B2 (ja) | 1987-11-30 | 1997-04-16 | 大正製薬株式会社 | 微粒子脂肪乳剤 |
| GB8811410D0 (en) | 1988-05-13 | 1988-06-15 | Unilever Plc | Treatment of skin disorders |
| US5015483A (en) | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
| JP2828655B2 (ja) | 1989-04-14 | 1998-11-25 | エーザイ株式会社 | 脂溶性薬物含有水性液 |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US5962243A (en) | 1990-04-18 | 1999-10-05 | Board Of Regents, The University Of Texas System | Methods for the identification of farnesyltransferase inhibitors |
| WO1992008685A1 (fr) | 1990-11-14 | 1992-05-29 | L'oreal | Composes amphiphiles non-ioniques derives du glycerol, leur procede de preparation, composes intermediaires correspondants et compositions contenant lesdits composes |
| SE502569C2 (sv) | 1991-05-31 | 1995-11-13 | British Tech Group | Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit |
| US5378461A (en) | 1991-07-12 | 1995-01-03 | Neigut; Stanley J. | Composition for the topical treatment of skin damage |
| US5605930A (en) | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
| US6461593B1 (en) | 1992-02-19 | 2002-10-08 | Biomedical And Clinical Research | Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease |
| AU676470B2 (en) | 1992-02-24 | 1997-03-13 | East Carolina University | Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof |
| US6093706A (en) | 1992-03-04 | 2000-07-25 | Bioresponse, L.L.C. | Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders |
| FR2697841B1 (fr) | 1992-11-12 | 1995-01-13 | Rhone Poulenc Rorer Sa | Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent. |
| US5602184A (en) | 1993-03-03 | 1997-02-11 | The United States Of America As Represented By Department Of Health And Human Services | Monoterpenes, sesquiterpenes and diterpenes as cancer therapy |
| AU6156494A (en) | 1993-03-08 | 1994-09-26 | Eisai Co. Ltd. | Phosphonic acid derivatives |
| DE59406065D1 (de) | 1993-03-24 | 1998-07-02 | Ciba Geigy Ag | Verfahren zur Herstellung einer Liposomendispersion im Hochdruckbereich |
| DE4327063A1 (de) | 1993-08-12 | 1995-02-16 | Kirsten Dr Westesen | Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften |
| US7083572B2 (en) | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
| DE4410238A1 (de) | 1994-03-25 | 1995-09-28 | Beiersdorf Ag | Hautpflegemittel |
| US20020049422A1 (en) | 1994-03-31 | 2002-04-25 | Brewitt Barbara A. | Homeopathic preparations |
| WO1996017626A2 (en) | 1994-12-06 | 1996-06-13 | Ryan Pharmaceuticals, Inc. | Water soluble ubiquinone compositions, prodrugs, and methods relating thereto |
| US6958150B2 (en) | 1994-12-15 | 2005-10-25 | Advance Biofactures Of Curacao, N.V. | Reduction of adipose tissue |
| US6005086A (en) | 1995-01-13 | 1999-12-21 | The Salk Institute For Biological Studies | Farnesoid activated receptor polypeptides, and nucleic acid encoding the same |
| DE19537027A1 (de) | 1995-10-05 | 1997-04-10 | Beiersdorf Ag | Hautpflegemittel für alte Haut |
| AU730969B2 (en) | 1995-10-19 | 2001-03-22 | University Of Washington | Discrete-length polyethylene glycols |
| US5944012A (en) | 1996-03-25 | 1999-08-31 | Pera; Ivo E. | Method for dispensing antioxidant vitamins by inhalation background of the invention |
| DE19615577A1 (de) | 1996-04-19 | 1997-10-23 | Beiersdorf Ag | Verwendung von Salicin als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen |
| US5891465A (en) | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
| GB9625895D0 (en) | 1996-12-13 | 1997-01-29 | Riley Patrick A | Novel compound useful as therapeutic agents and assay reagents |
| ES2159938T3 (es) | 1997-02-11 | 2001-10-16 | Mse Pharmazeutika Gmbh | Preparados transdermicos, orales e intravenosos de 2,3-dimetoxi-5-metil-6-decaprenil-1,4-benzoquinona. |
| US20040228910A1 (en) | 1997-02-11 | 2004-11-18 | Mse Pharmazeutika Gmbh | Transdermal, oral and intravenous formulations of 2, 3-dimethoxy-5-methyl-6-decaprenyl-1, 4-benzoquinone |
| WO1998035658A2 (de) | 1997-02-12 | 1998-08-20 | Mse Pharmazeutika Gmbh | Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon |
| IT1291113B1 (it) | 1997-03-20 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Composizione nutritiva terapeutica per soggetti affetti da diabete mellito |
| US6599513B2 (en) | 1997-05-27 | 2003-07-29 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
| US6372234B1 (en) | 1997-05-27 | 2002-04-16 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
| JP2001514209A (ja) | 1997-09-04 | 2001-09-11 | バイオゾーン ラボラトリーズ，インコーポレイテッド | 経口リポソーム送達系 |
| US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| AU1289899A (en) | 1997-10-31 | 1999-05-24 | Arch Development Corporation | Methods and compositions for regulation of 5-alpha reductase activity |
| WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
| US6372880B1 (en) | 1997-12-25 | 2002-04-16 | Mitsui Chemicals, Inc. | Copolymer and process for preparing the same |
| US6048846A (en) | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
| EP1065931A4 (de) | 1998-04-02 | 2006-10-11 | Avicena Group Inc | Eine kombination einer kreatin-verbindung und eines zweiten stoffes enthaltende zusammensetzungen |
| CA2325798C (en) | 1998-04-14 | 2008-08-26 | Kyowa Hakko Kogyo Co., Ltd. | A process for producing isoprenoid compounds by microorganisms and a method for screening compounds with antibiotic or weeding activity |
| US6503523B2 (en) | 1998-05-07 | 2003-01-07 | Gs Development A.B. | Skin care agents containing combinations of active agents consisting of vitamin a derivatives and UBI- or plastoquinones |
| IL140276A0 (en) | 1998-06-19 | 2002-02-10 | Rtp Pharma Inc | Processes to generate submicron particles of water-insoluble compounds |
| US6093743A (en) | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| DE19828081C2 (de) | 1998-06-24 | 2000-08-10 | Cognis Deutschland Gmbh | W/O-Emulsionsgrundlagen |
| WO2000004230A1 (de) | 1998-07-16 | 2000-01-27 | Cognis Deutschland Gmbh | Verwendung von pit-emulsionen |
| AU750313B2 (en) | 1998-07-27 | 2002-07-18 | St. Jude Pharmaceuticals, Inc. | Chemically induced intracellular hyperthermia |
| WO2000007607A1 (en) | 1998-08-04 | 2000-02-17 | Kosbab, John, V. | Nutrient and therapeutic compositions for the treatment of cancer |
| US6048886A (en) | 1998-10-05 | 2000-04-11 | Neigut; Stanley | Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin |
| IT1304406B1 (it) | 1998-10-21 | 2001-03-19 | Danital Italia S R L | Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3. |
| US20050123938A1 (en) | 1999-01-06 | 2005-06-09 | Chondrogene Limited | Method for the detection of osteoarthritis related gene transcripts in blood |
| US20050019268A1 (en) | 1999-02-11 | 2005-01-27 | Mse Pharmazeutika Gmbh | Spray containing ubiquinone Qn |
| US20040034107A1 (en) | 1999-02-11 | 2004-02-19 | Mse Pharmazeutika Gmbh | Ubiquinone Qn for the treatment of pain |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US20030104048A1 (en) | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| US6632443B2 (en) | 2000-02-23 | 2003-10-14 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
| US6140067A (en) | 1999-04-30 | 2000-10-31 | Mitokor | Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus |
| US6482943B1 (en) | 1999-04-30 | 2002-11-19 | Slil Biomedical Corporation | Quinones as disease therapies |
| US6803193B1 (en) | 1999-06-23 | 2004-10-12 | The Penn State Research Foundation | Methods to identify modulators of the mevalonate pathway in sterol synthesis |
| US6242491B1 (en) | 1999-06-25 | 2001-06-05 | Rima Kaddurah-Daouk | Use of creatine or creatine compounds for skin preservation |
| US6960439B2 (en) | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
| EP1064913B1 (de) | 1999-07-02 | 2005-09-14 | Cognis IP Management GmbH | Mikrokapseln - III |
| US20030104080A1 (en) | 1999-09-07 | 2003-06-05 | Singh Parashu Ram | Topical urea composition |
| US6630160B1 (en) | 1999-09-07 | 2003-10-07 | Genetic Services Management, Inc. | Process to modulate disease risk with doses of a nutraceutical |
| US7005274B1 (en) | 1999-09-15 | 2006-02-28 | Migenix Corp. | Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass |
| KR20020063877A (ko) | 1999-10-14 | 2002-08-05 | 니신 오일 밀스 가부시키가이샤 | 피부개선제, 피부노화 방지제, 미백제 및 피부외용제 |
| US7309688B2 (en) | 2000-10-27 | 2007-12-18 | Johnson & Johnson Consumer Companies | Topical anti-cancer compositions and methods of use thereof |
| US20020049176A1 (en) | 1999-11-10 | 2002-04-25 | Anderson Christen M. | Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery |
| US20030180352A1 (en) | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7250174B2 (en) | 1999-12-07 | 2007-07-31 | Schott Ag | Cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same |
| US7083780B2 (en) | 1999-12-11 | 2006-08-01 | Cognis Deutschland Gmbh & Co. Kg | Cosmetic composition containing hydroxyethers |
| AU5440901A (en) | 1999-12-20 | 2001-07-03 | Cognis France, S.A. | Cosmetic and/or pharmaceutical preparations |
| AUPQ515000A0 (en) | 2000-01-19 | 2000-02-10 | Grigg, Geoffrey Walter | Treatment of uv induced immunosuppression |
| DE60124504T2 (de) | 2000-02-04 | 2007-09-20 | Takeda Pharmaceutical Co. Ltd. | Stabile emulsionszubereitungen |
| AU782564B2 (en) | 2000-02-09 | 2005-08-11 | Paul A Sneed | Treatment of fibromyalgia with Ubiquinone 10 and succinic acid |
| FR2804864B1 (fr) | 2000-02-11 | 2003-04-04 | Serobiologiques Lab Sa | Extraits de residus issus de la fabrication du vin et leur utilisation en cosmetique ou pharmacologie |
| US20020044913A1 (en) | 2000-02-11 | 2002-04-18 | Hamilton Nathan D. | Cosmetics to support skin metabolism |
| ATE479419T1 (de) | 2000-02-17 | 2010-09-15 | Basf Se | Wässrige dispersion wasserunlöslicher organischer uv-filtersubstanzen |
| DE10007322A1 (de) | 2000-02-17 | 2001-08-23 | Cognis Deutschland Gmbh | Perlglanzmittel |
| FR2805464B1 (fr) | 2000-02-25 | 2003-02-14 | Serobiologiques Lab Sa | Preparations cosmetiques contenant des extraits de la plante mourera fluviatilis |
| DE10009996B4 (de) | 2000-03-02 | 2005-10-13 | Cognis Ip Management Gmbh | Feststoffgranulate mit monodisperser Korngrößenverteilung, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung |
| US6664287B2 (en) | 2000-03-15 | 2003-12-16 | Bethesda Pharmaceuticals, Inc. | Antioxidants |
| US6866864B2 (en) | 2000-03-20 | 2005-03-15 | Ahmed Mousa | Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders |
| US6447760B2 (en) | 2000-05-08 | 2002-09-10 | Playtex Products, Inc. | Sunless tanning compositions |
| JP4421801B2 (ja) | 2000-05-09 | 2010-02-24 | 株式会社カネカ | 補酵素ｑを有効成分とする皮膚用組成物 |
| US6468552B1 (en) | 2000-06-02 | 2002-10-22 | Neutrogena Corporation | Stabilized compositions containing oxygen-labile active agents |
| SE0002189D0 (sv) | 2000-06-09 | 2000-06-09 | Metcon Medicin Ab | New method and assay |
| DE10031703A1 (de) | 2000-06-29 | 2002-01-10 | Beiersdorf Ag | Verwendung von Calcium freisetzenden oder bindenden Substanzen zur gezielten Schächung oder Stärkung der Barrierefunktion der Haut |
| EP1170015A1 (de) | 2000-07-06 | 2002-01-09 | Laboratoires Serobiologiques(Societe Anonyme) | Verwendung von Extrakten des Pilzes Grifola frondosa |
| DE10033022A1 (de) | 2000-07-07 | 2002-01-17 | Cognis Deutschland Gmbh | Aerosole |
| US20030012825A1 (en) | 2000-07-10 | 2003-01-16 | Charles Kapper | Metallized molecule therapies |
| US6465517B1 (en) | 2000-07-11 | 2002-10-15 | N.V. Nutricia | Composition for the treatment of migraine |
| DE10034619A1 (de) | 2000-07-17 | 2002-01-31 | Cognis Deutschland Gmbh | Aniontensidfreie niedrigviskose Trübungsmittel |
| DE10036655A1 (de) | 2000-07-26 | 2002-02-07 | Basf Ag | Kosmetische oder dermatologische Zubereitungen zur Vermeidung von Hautschädigungen durch Peroxide |
| DE10036799A1 (de) | 2000-07-28 | 2002-02-07 | Beiersdorf Ag | Neues Mittel zur Behandlung der Haare und der Kopfhaut |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US20020045230A1 (en) | 2000-08-14 | 2002-04-18 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| US6441050B1 (en) | 2000-08-29 | 2002-08-27 | Raj K. Chopra | Palatable oral coenzyme Q liquid |
| FR2813195B1 (fr) | 2000-08-29 | 2003-04-04 | Serobiologiques Lab Sa | Utilisation d'extraits de la plante cassia alata dans des produits de soin |
| DE10048260A1 (de) | 2000-09-29 | 2002-04-11 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Aminoguanidin und/oder dessen Derivaten und Strukturanaloga zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung |
| DE10053328A1 (de) | 2000-10-27 | 2002-05-08 | Cognis Deutschland Gmbh | Kosmetische Zubereitungen |
| US6403116B1 (en) | 2000-11-03 | 2002-06-11 | Triarco Inductries, Inc. | Coenzyme Q10 formulation |
| US6689385B2 (en) | 2000-11-03 | 2004-02-10 | Chronorx Llc | Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
| IT1317938B1 (it) | 2000-11-17 | 2003-07-15 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento di alterazioni delmetabolismo lipidico, delle forme allergiche e per attivare le difese |
| US20070003536A1 (en) | 2000-11-21 | 2007-01-04 | Zimmerman Amy C | Topical skin compositions, their preparation, and their use |
| AUPR177300A0 (en) | 2000-11-29 | 2000-12-21 | Centre For Molecular Biology And Medicine | Therapeutic methods |
| JP2004515508A (ja) | 2000-12-16 | 2004-05-27 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 化合物の健康促進組成物 |
| DE10064818A1 (de) | 2000-12-22 | 2002-06-27 | Basf Ag | Verwendung von Chroman-Derivaten in kosmetischen oder dermatologischen Zubreitungen |
| US6806069B2 (en) | 2001-01-09 | 2004-10-19 | Pharmachem Laboratories, Inc. | Ubiquinone composition and methods related thereto |
| FR2819414A1 (fr) | 2001-01-15 | 2002-07-19 | Cognis France Sa | Preparations cosmetiques et/ou pharmaceutiques comprenant des extraits de plantes dites a resurrection |
| WO2002056823A2 (en) | 2001-01-18 | 2002-07-25 | Arnold Hoffman | Redox therapy for tumors |
| JP2004521122A (ja) | 2001-01-25 | 2004-07-15 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン類似体の非経口製剤 |
| NL1017205C2 (nl) | 2001-01-26 | 2002-07-29 | Adriaan Emanuel Hendricus Wiel | Medicinale en cosmetische toepassing van hop en co-enzym Q10. |
| ITRM20010044A1 (it) | 2001-01-29 | 2002-07-29 | Sigma Tau Healthscience Spa | Integratore alimentare ad effetto dimagrante. |
| EP2067486A1 (de) | 2001-01-31 | 2009-06-10 | Biogen Idec Inc. | Verwendung von CD23 Antagonisten zur Behandlung von neoplastischen Erkrankungen |
| ITMI20010204A1 (it) | 2001-02-02 | 2002-08-02 | Hunza Di Marazzita Maria Carme | Specialita' terapeutiche dotate di attivita' antiossidante ed in grado di controllare l'eccesso del peso corporeo |
| FR2821624B1 (fr) | 2001-03-01 | 2004-01-02 | Sod Conseils Rech Applic | Nouveau polynucleotide utilisable pour moduler la proliferation des cellules cancereuses |
| CA2439078C (en) | 2001-03-09 | 2009-08-25 | Societe Des Produits Nestle S.A. | Composition improving age-related physiological deficits and increasing longevity |
| DE10113053A1 (de) | 2001-03-15 | 2002-09-19 | Beiersdorf Ag | Selbstschäumende oder schaumförmige Zubereitungen mit anorganischen Gelbildnern und organischen Hydrololloiden |
| DE10113050A1 (de) | 2001-03-15 | 2002-09-19 | Beiersdorf Ag | Selbstschäumende oder schaumförmige Zubereitungen organischen Hydrokolloiden |
| DE10113046A1 (de) | 2001-03-15 | 2002-09-26 | Beiersdorf Ag | Selbstschäumende schaumförmige Zubereitungen mit organischen Hydrokolliden und partikulären hydrophobisierten und/oder ölabsorbierenden Festkörpersubstanzen |
| DE60211581D1 (de) | 2001-03-23 | 2006-06-29 | Oreal | Hautbehandlungsmittel enthaltend Fasern und Ubichinone |
| US20030031688A1 (en) | 2001-04-02 | 2003-02-13 | Dipak Ghosh | Cosmetic composition with improved skin moisturizing properties |
| US6727234B2 (en) | 2001-04-03 | 2004-04-27 | University Of Iowa Research Foundation | Isoprenoid analog compounds and methods of making and use thereof |
| US6469061B1 (en) | 2001-04-04 | 2002-10-22 | Ramot University Authority For Applied Research And Industrial Development Limited | Jasmonate pharmaceutical composition for treatment of cancer |
| DE10118269A1 (de) | 2001-04-12 | 2002-10-17 | Cognis Deutschland Gmbh | Kosmetische Zubereitungen |
| US6686485B2 (en) | 2001-04-19 | 2004-02-03 | Daniel David West | Synthesis of coenzyme Q10, ubiquinone |
| US20040049022A1 (en) | 2001-04-24 | 2004-03-11 | Nyce Jonathan W. | Composition & methods for treatment and screening |
| WO2002085297A2 (en) | 2001-04-24 | 2002-10-31 | East Carolina University | Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease |
| AU2002256359A1 (en) | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Antisense and anti-inflammatory based compositions to treat respiratory disorders |
| US6582723B2 (en) | 2001-05-03 | 2003-06-24 | Wayne F. Gorsek | Cancer immune composition for prevention and treatment of individuals |
| JP3742602B2 (ja) | 2001-05-09 | 2006-02-08 | 株式会社カネカ | 還元型補酵素ｑの安定な溶液 |
| CA2443191A1 (en) | 2001-05-10 | 2002-11-21 | Kaneka Corporation | Compositions for transmucosal administration containing coenzyme q as the active ingredient |
| JP4603192B2 (ja) | 2001-05-10 | 2010-12-22 | 株式会社カネカ | 毛髪頭皮用組成物 |
| GB0111279D0 (en) | 2001-05-10 | 2001-06-27 | Nycomed Imaging As | Radiolabelled liposomes |
| DE10123771B4 (de) | 2001-05-16 | 2019-01-10 | Beiersdorf Ag | Verwendung von Elektrolyten zur Stärkung der Barrierefunktion der Haut |
| EP1260212A1 (de) | 2001-05-21 | 2002-11-27 | Cognis France S.A. | Kosmetische Mittel |
| US20050118151A1 (en) | 2001-05-29 | 2005-06-02 | Syddansk Universitet | Proteins in diabetes proteome anlysis |
| MXPA03010888A (es) | 2001-05-30 | 2004-02-27 | Laxdale Ltd | Coenzimas q y acido eicosapentaenoico (epa). |
| US20030138792A1 (en) | 2001-05-31 | 2003-07-24 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer |
| US7091241B2 (en) | 2001-06-01 | 2006-08-15 | Summa Health System | Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3 |
| EP1262167A1 (de) | 2001-06-01 | 2002-12-04 | Cognis France S.A. | Kosmetische Zubereitungen enthaltend ein Extrakt von keimenden Pflanzen |
| US6506915B1 (en) | 2001-06-14 | 2003-01-14 | Daniel David West | Synthesis of coenzyme Q10 ubiquinone |
| US6696060B2 (en) | 2001-06-14 | 2004-02-24 | Clearant, Inc. | Methods for sterilizing preparations of monoclonal immunoglobulins |
| FR2826017B1 (fr) | 2001-06-15 | 2004-06-11 | Cognis France Sa | Melanges de tensioactifs |
| SE0102380D0 (sv) | 2001-07-02 | 2001-07-02 | Macronova Ab | Kräm för behandling av åldersförändringar i huden hos människa |
| DE10133198A1 (de) | 2001-07-07 | 2003-01-23 | Beiersdorf Ag | Kreatin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut |
| JP2003020495A (ja) | 2001-07-10 | 2003-01-24 | Cognis Japan Ltd | 油脂組成物 |
| US20030207834A1 (en) | 2001-07-10 | 2003-11-06 | Dale Roderic M.K. | Oligonucleotide-containing pharmacological compositions and their use |
| CH695085A5 (de) | 2001-07-13 | 2005-12-15 | Mibelle Ag Cosmetics | Formulierungen zur Pflege der Haut nach Laserbehandlungen und/oder chemischen Peelings und Verwendung der Formulierungen. |
| TWI235146B (en) | 2001-07-16 | 2005-07-01 | Kaneka Corp | Method of stabilizing reduced coenzyme q10 and method of acidic crystallization |
| WO2003007889A2 (en) | 2001-07-17 | 2003-01-30 | Research Development Foundation | Therapeutic agents comprising pro-apoptotic proteins |
| FR2827603B1 (fr) | 2001-07-18 | 2003-10-17 | Oreal | Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques |
| US7758893B2 (en) | 2001-07-27 | 2010-07-20 | N.V. Nutricia | Enteral compositions for the prevention and/or treatment of sepsis |
| EP1281392A1 (de) | 2001-08-02 | 2003-02-05 | Cognis France S.A. | Kosmetische und/oder pharmaceutische Zubereitungen enthaltend Pflanzenextrakte |
| US6503506B1 (en) | 2001-08-10 | 2003-01-07 | Millenium Biotechnologies, Inc. | Nutrient therapy for immuno-compromised patients |
| DE10139580A1 (de) | 2001-08-10 | 2003-02-20 | Beiersdorf Ag | Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen mit einem Gehalt an Sterinen und/oder C12-C40-Fettsäuren |
| DE10143963A1 (de) | 2001-09-07 | 2003-03-27 | Basf Ag | Kosmetische und dermatologische Zubereitungen in Form von W/O-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon |
| DE10143964A1 (de) | 2001-09-07 | 2003-03-27 | Basf Ag | Emulgatorarme oder emulgatorfreie Systeme vom Typ Öl-in-Wasser mit einem Gehalt an Stabilisatoren und einem aminosubstituierten Hydroxybenzophenon |
| DE10143962A1 (de) | 2001-09-07 | 2003-03-27 | Basf Ag | Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon |
| US7425320B2 (en) | 2001-09-18 | 2008-09-16 | Ciba Specialty Chemicals Corp | Use of guaiol for treating the skin |
| DE10150725A1 (de) | 2001-10-13 | 2003-04-17 | Cognis Deutschland Gmbh | Aniontensidfreie niedrigviskose Trübungsmittel |
| AU2002335040A1 (en) | 2001-10-16 | 2003-04-28 | Atherogenics, Inc. | Protection against oxidative stress and inflammation by a cytoprotective response element |
| US7560123B2 (en) | 2004-08-12 | 2009-07-14 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
| US6723527B2 (en) | 2001-10-26 | 2004-04-20 | Board Of Regents, The University Of Texas System | Methods for determining toxicity reversing agents |
| DE50206759D1 (de) | 2001-10-26 | 2006-06-14 | Cognis Ip Man Gmbh | Imprägnierlösung für kosmetiktücher |
| MXPA04004219A (es) | 2001-11-03 | 2004-09-10 | Astrazeneca Ab | Derivados de quinazolina como agentes antitumorales. |
| US20030105027A1 (en) | 2001-11-06 | 2003-06-05 | Rosenbloom Richard A. | Nutritional supplements and methods for prevention, reduction and treatment of radiation injury |
| US6753325B2 (en) | 2001-11-06 | 2004-06-22 | The Quigley Corporation | Composition and method for prevention, reduction and treatment of radiation dermatitis |
| US7435725B2 (en) | 2001-11-06 | 2008-10-14 | The Quigly Corporation | Oral compositions and methods for prevention, reduction and treatment of radiation injury |
| US20030118536A1 (en) | 2001-11-06 | 2003-06-26 | Rosenbloom Richard A. | Topical compositions and methods for treatment of adverse effects of ionizing radiation |
| US20030105031A1 (en) | 2001-11-06 | 2003-06-05 | Rosenbloom Richard A. | Methods for the treatment of skin disorders |
| EP1451580B1 (de) | 2001-11-09 | 2009-07-08 | Medstar Research Institute | Verfahren zur verwendung physiologischer marker für die abschätzung eines herz-kreislauf-risikos |
| DE10155769A1 (de) | 2001-11-14 | 2003-05-22 | Cognis Deutschland Gmbh | Kosmetische und/oder pharmazeutische Emulsionen |
| DE10160682A1 (de) | 2001-12-11 | 2003-06-18 | Cognis Deutschland Gmbh | Emollients und kosmetische Zusammensetzungen |
| US6652891B2 (en) | 2001-12-12 | 2003-11-25 | Herbasway Laboratories, Llc | Co-enzyme Q10 dietary supplement |
| DE10162026A1 (de) | 2001-12-18 | 2003-07-03 | Cognis Deutschland Gmbh | Hochkonzentriert fließfähige Perlglanzkonzentrate |
| DE10162351A1 (de) | 2001-12-18 | 2003-07-03 | Cognis Deutschland Gmbh | Kosmetische und/oder pharmazeutische Emulsionen |
| ITRM20010755A1 (it) | 2001-12-20 | 2003-06-20 | Simonelli Giuseppe | Uso del chinone q10 per il trattamento delle malattie oculari. |
| TWI305547B (en) | 2001-12-27 | 2009-01-21 | Kaneka Corp | Processes for producing coenzyme q10 |
| US20030129253A1 (en) | 2002-01-03 | 2003-07-10 | Milley Christopher J. | Stable aqueous suspension |
| TW200302056A (en) | 2002-01-18 | 2003-08-01 | Kaneka Corp | Method for stabilizing reduced coenzyme Q10 and composition therefor |
| AU2003206690A1 (en) | 2002-01-18 | 2003-07-30 | Basf Aktiengesellschaft | Cosmetic or dermatological preparations for preventing damages to skin caused by peroxides |
| CN100473374C (zh) | 2002-01-31 | 2009-04-01 | 西巴特殊化学品控股有限公司 | 微粉颜料混合物 |
| CA2473228C (en) | 2002-02-12 | 2010-12-14 | Dsm Ip Assets B.V. | Sunscreen compositions as well as dihydropyridines and dihydropyranes |
| ES2302913T3 (es) | 2002-02-14 | 2008-08-01 | Dsm Ip Assets B.V. | Formulaciones a base de coenzima q-10. |
| EP1340486A1 (de) | 2002-03-01 | 2003-09-03 | Cognis France S.A. | Verwendung von Zuckerestern |
| US20030167556A1 (en) | 2002-03-05 | 2003-09-11 | Consumers Choice Systems, Inc. | Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging |
| DE10254315A1 (de) | 2002-03-15 | 2003-10-02 | Cognis Deutschland Gmbh | Emollients und kosmetische Zubereitungen |
| CN1856708A (zh) | 2002-03-20 | 2006-11-01 | 普赖德普罗特奥米克斯公司 | 人糖尿病介导蛋白 |
| TW200304372A (en) | 2002-03-20 | 2003-10-01 | Kanegafuchi Chemical Ind | Compositions for diabetes |
| DE10212528A1 (de) | 2002-03-21 | 2003-10-02 | Cognis Deutschland Gmbh | Ölphasen für kosmetische Mittel |
| DE10213957A1 (de) | 2002-03-28 | 2003-10-09 | Beiersdorf Ag | Vernetzte kosmetische oder pharmazeutische phospholipidhaltige Gele und Emulsionen auf der Basis von ethylenoxidhaltigen oder propylenoxidhaltigen Emulgatoren |
| US7811594B2 (en) | 2002-03-28 | 2010-10-12 | Beiersdorf Ag | Crosslinked oil droplet-based cosmetic or pharmaceutical emulsions |
| US20040101874A1 (en) | 2002-04-12 | 2004-05-27 | Mitokor Inc. | Targets for therapeutic intervention identified in the mitochondrial proteome |
| DE10217474A1 (de) | 2002-04-19 | 2003-11-06 | Cognis Deutschland Gmbh | Sonnenschutzemulsion mit Schaumspender |
| US20060193905A1 (en) | 2002-05-14 | 2006-08-31 | University Of Louisville Research Foundation, Inc. | Direct cellular energy delivery system |
| JP2005531570A (ja) | 2002-05-23 | 2005-10-20 | ユーエムディー， インコーポレイテッド | 貫粘膜薬物送達及び凍結保護のための組成物及び方法 |
| DE10223486A1 (de) | 2002-05-27 | 2003-12-11 | Beiersdorf Ag | Kosmetische und/oder dermatologische Zubereitung mit 2,3-Dibenzylbutyrolactonen |
| ES2269955T3 (es) | 2002-06-03 | 2007-04-01 | Ciba Specialty Chemicals Holding Inc. | Formulaciones para proteccion de uv. |
| DE10226018A1 (de) | 2002-06-12 | 2003-12-24 | Cognis Deutschland Gmbh | Zubereitungen mit konjugiertem Linolalkohol |
| US7182950B2 (en) | 2002-06-12 | 2007-02-27 | Nutralease Ltd. | Nano-sized self-assembled liquid dilutable vehicles |
| US7147841B2 (en) | 2002-06-17 | 2006-12-12 | Ciba Specialty Chemicals Corporation | Formulation of UV absorbers by incorporation in solid lipid nanoparticles |
| WO2004003564A2 (de) | 2002-06-26 | 2004-01-08 | Europroteome Ag | Tumormarker und ihre verwendung zur diagnose und therapie von tumorerkrankungen |
| US7060733B2 (en) | 2002-08-15 | 2006-06-13 | The Regents Of The University Of California | Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species |
| US20060205771A1 (en) | 2002-09-25 | 2006-09-14 | Mark Noble | Caspase inhibitors as anticancer agents |
| US6953786B2 (en) | 2002-10-01 | 2005-10-11 | The Regents Of The University Of California | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
| FR2845602B1 (fr) | 2002-10-11 | 2005-07-08 | Servier Lab | Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent |
| US7083813B2 (en) | 2002-11-06 | 2006-08-01 | The Quigley Corporation | Methods for the treatment of peripheral neural and vascular ailments |
| EP1421929A3 (de) | 2002-11-21 | 2004-11-24 | Cognis Deutschland GmbH & Co. KG | Emollients und kosmetische Zubereitungen |
| DE10256881A1 (de) | 2002-12-05 | 2004-06-24 | Beiersdorf Ag | Neue topische Verwendung von Bis-Arylimidazo[1,2-a]thiolanderivaten |
| US20040110848A1 (en) | 2002-12-10 | 2004-06-10 | Peffley Dennis M | Method and kit for treating cancer |
| JP2006509510A (ja) | 2002-12-16 | 2006-03-23 | ガーバン インスティテュート オブ メディカル リサーチ | 摂食障害またはグルコース取込み障害の治療法と代謝修正およびそのための治療薬の同定のための方法 |
| AU2003302340B8 (en) | 2002-12-24 | 2008-09-11 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| ES2526695T3 (es) | 2003-01-02 | 2015-01-14 | Gerard M. Housey | Moduladores de IRS |
| US20090036516A1 (en) | 2003-01-13 | 2009-02-05 | Ctg Pharma S.R.L. | Compounds for treating metabolic syndrome |
| US8187575B2 (en) | 2003-01-20 | 2012-05-29 | BASF SE Ludwigshafen | Triazine derivatives as UV absorbers |
| WO2004069216A1 (en) | 2003-02-03 | 2004-08-19 | Dsm Ip Assets B.V. | Novel stabilized cinnamic ester sunscreen compositions |
| US7258876B2 (en) | 2003-02-05 | 2007-08-21 | Craig Bozzacco | Topical composition for treating infectious conditions of skin and mucosa |
| CN1208052C (zh) | 2003-03-20 | 2005-06-29 | 上海家化联合股份有限公司 | 一种辅酶q10前体脂质体及其制备方法 |
| US7311897B2 (en) | 2003-03-24 | 2007-12-25 | Ciba Specialty Chemicals Corporation | Symmetrical triazine derivatives |
| CA2521149C (en) | 2003-04-08 | 2014-03-25 | Barrie Tan | Annatto extract compositions, including geranyl geraniols and methods of use |
| US20050037102A1 (en) | 2003-07-18 | 2005-02-17 | Barrie Tan | Annatto extract compositions including tocotrienols and tocopherols and methods of use |
| JP2004321171A (ja) | 2003-04-11 | 2004-11-18 | Fancl Corp | 飲食品 |
| EP1473043A1 (de) | 2003-04-29 | 2004-11-03 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pharmazeutische Kombination zur Behandlung von Krankheiten die mit Zellproliferation, Migration oder Apoptose der Myeloma Zellen oder Angiogenese verbunden sind |
| JP2004345988A (ja) | 2003-05-21 | 2004-12-09 | Eisai Co Ltd | リボフラビン系化合物を含む医薬組成物 |
| US7438903B2 (en) | 2003-06-06 | 2008-10-21 | Nbty, Inc. | Methods and compositions that enhance bioavailability of coenzyme-Q10 |
| US20040253323A1 (en) | 2003-06-11 | 2004-12-16 | Giles Brian C. | Ionic cancer therapy and methods for using same in the treatment of tumors and metastasis |
| KR20060082791A (ko) | 2003-06-25 | 2006-07-19 | 찰스 에르윈 | 코엔자임 ｑ10의 전달을 증가시키기 위한 화학적 배합물 및방법 |
| US20050026848A1 (en) | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026879A1 (en) | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US8802161B2 (en) * | 2003-08-02 | 2014-08-12 | Florida Agricultural And Mechanical University | Herbal composition and method of use for the treatment of cancer |
| US20060035981A1 (en) | 2003-08-02 | 2006-02-16 | Mazzio Elizabeth A | Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment |
| US20070248693A1 (en) | 2003-08-02 | 2007-10-25 | Elizabeth Mazzio | Nutraceutical composition and method of use for treatment / prevention of cancer |
| US20080069779A1 (en) | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
| US20050036976A1 (en) | 2003-08-12 | 2005-02-17 | Joel Rubin | Topical skin care composition |
| JP2007503418A (ja) | 2003-08-27 | 2007-02-22 | バイヤースドルフ・アクチエンゲゼルシヤフト | 局所使用中に個別には感知不能になる外皮を有するカプセル |
| US7169385B2 (en) | 2003-09-29 | 2007-01-30 | Ronald G. Udell | Solubilized CoQ-10 and carnitine |
| AU2004277951B2 (en) | 2003-09-29 | 2010-11-11 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
| US8124072B2 (en) | 2003-09-29 | 2012-02-28 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
| CN1863506A (zh) | 2003-10-02 | 2006-11-15 | 塞姆柏奥希斯遗传学公司 | 制备含活性成分油体的方法 |
| DE10347218A1 (de) | 2003-10-10 | 2005-05-12 | Cognis Deutschland Gmbh | Sonnenschutzmittel |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| DE10347940A1 (de) | 2003-10-15 | 2005-05-19 | Cognis Deutschland Gmbh & Co. Kg | Selbstemulgierende Zubereitungen |
| CN1870982B (zh) | 2003-10-31 | 2010-05-26 | 株式会社钟化 | 含还原型辅酶q的组合物 |
| ES2334797T3 (es) | 2003-11-05 | 2010-03-16 | Dsm Ip Assets B.V. | Composicion protectora de la luz con una cantidad total reducida de filtro uv que contiene un filtro uv a base de polisiloxano. |
| US20050100537A1 (en) | 2003-11-10 | 2005-05-12 | Evans Gregory S. | Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals |
| DE10354052A1 (de) | 2003-11-17 | 2005-06-16 | Beiersdorf Ag | Kosmetikum mit empfindlichen Inhaltsstoffen |
| US20050118235A1 (en) | 2003-12-02 | 2005-06-02 | Shiguang Yu | Dietary non-essential amino acid tyrosine regulates the body weight of animals through regulating the animal appetite or food intake |
| EP1694623A4 (de) * | 2003-12-05 | 2007-01-17 | Zymes Inc | Praktische, kostengünstige synthese von ubichinonen |
| CA2549509C (en) | 2003-12-18 | 2014-07-22 | Nestec S.A. | Composition for improving skin, hair and coat health containing flavanones |
| CA2553690C (en) | 2004-01-22 | 2016-05-24 | Sung Lan Hsia | Topical co-enzyme q10 formulations and methods of use |
| US20050226947A1 (en) | 2004-02-04 | 2005-10-13 | Dale Kern | Agents for sequestering serum aging factors and uses therefore |
| US20070149618A1 (en) | 2004-02-17 | 2007-06-28 | Action Medicines, S.L. | Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis |
| WO2005079143A2 (en) | 2004-02-19 | 2005-09-01 | Occell Inc. | Topical formulations for the treatment of skin conditions |
| WO2005084452A1 (en) | 2004-02-23 | 2005-09-15 | The Texas A & M University System | Antioxidant compositions and methods of use thereof |
| US7780873B2 (en) | 2004-02-23 | 2010-08-24 | Texas A&M University System | Bioactive complexes compositions and methods of use thereof |
| US20050202521A1 (en) | 2004-03-10 | 2005-09-15 | Albert Crum | Methods of assessing the need for and the effectiveness of therapy with antioxidants |
| DE102004014615A1 (de) | 2004-03-23 | 2005-10-13 | Beiersdorf Ag | Taurinhaltige Zubereitungen zur Verbesserung der Hautbarriere |
| BRPI0509712A (pt) | 2004-04-06 | 2007-09-18 | Basf Ag | método de proteger a pele humana ou o cabelo humano da radiação ultravioleta, formulação para cuidados pessoais contendo protetor solar para proteger a pele humana ou cabelo humano da radiação ultravioleta, e, partìcula tratada na superfìcie |
| US20050226858A1 (en) | 2004-04-09 | 2005-10-13 | Kaneka Corporation | Compositions containing reduced coenzyme Q10 and carotenoid |
| US7723569B2 (en) | 2004-04-30 | 2010-05-25 | National Institute Of Agrobiological Sciences | Method for producing ubiquinone-10 in plant |
| US7351739B2 (en) | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
| IL161899A0 (en) * | 2004-05-10 | 2005-11-20 | Hoffman Arnold | Kit for treatment of cancer |
| JP2005323573A (ja) | 2004-05-17 | 2005-11-24 | Sumitomo Pharmaceut Co Ltd | 遺伝子発現データ解析方法および、疾患マーカー遺伝子の選抜法とその利用 |
| WO2005111224A2 (en) | 2004-05-18 | 2005-11-24 | Kemijski Institut | Water-soluble coenzyme q10 in inclusion complex with beta-cyclodextrin, process of preparing, and use thereof |
| RU2411029C9 (ru) | 2004-05-24 | 2011-10-20 | Басф Акциенгезельшафт | Кератинсвязывающие полипептиды |
| KR20050112942A (ko) | 2004-05-28 | 2005-12-01 | 주식회사 뉴트렉스테크놀러지 | 비만 억제용 조성물 |
| WO2005123075A2 (en) | 2004-06-08 | 2005-12-29 | University Of Florida Research Foundation, Inc. | Controlling angiogenesis with anabaseine analogs |
| CN101005828B (zh) | 2004-06-17 | 2012-01-11 | 维尔恩公司 | 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物 |
| EP1761271B1 (de) | 2004-06-18 | 2008-12-03 | Symrise GmbH & Co. KG | Brombeerextrakt |
| KR20070032795A (ko) | 2004-06-21 | 2007-03-22 | 허치슨 메디파르마 엔터프라이즈 리미티드 | 항암 화학요법 |
| JP2008504319A (ja) | 2004-06-28 | 2008-02-14 | ディーエスエム アイピー アセッツ ビー．ブイ． | タンパク質水解物を含有する化粧品組成物 |
| CA2573456A1 (en) | 2004-07-13 | 2006-01-19 | Eleonore Froehlich | Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers |
| US20060069068A1 (en) | 2004-07-15 | 2006-03-30 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the treatment of diseases characterized by pathological calcification |
| JP2008508301A (ja) | 2004-07-28 | 2008-03-21 | エム． プレヴァ，レイモンド | エミュー油と果実の組成物 |
| JP2006070016A (ja) | 2004-08-02 | 2006-03-16 | Kaneka Corp | 還元型補酵素ｑを含有する美白用組成物 |
| WO2006017494A2 (en) | 2004-08-02 | 2006-02-16 | Elizabeth Mazzio | Inhibition of anaerobic glucose metabolism |
| US20090137556A1 (en) | 2004-08-18 | 2009-05-28 | Ace Aps | Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists |
| WO2006023342A2 (en) | 2004-08-20 | 2006-03-02 | Tishcon Corp | Synergistic conjugated linoleic acid (cla) and carnitine combination |
| US20060051462A1 (en) | 2004-09-03 | 2006-03-09 | Wang Jimmy X | Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients |
| CA2578302C (en) * | 2004-09-07 | 2013-01-08 | Universite Laval | Composition and method for inducing or restoring locomotor functions in an animal |
| US7288263B2 (en) | 2004-09-13 | 2007-10-30 | Evera Laboratories, Llc | Compositions and methods for treatment of skin discoloration |
| ZA200703087B (en) | 2004-09-17 | 2009-04-29 | Inst Of Medicinal Biotechno | Methods and compositions for the treatment of hyperlipidemia |
| US20060062755A1 (en) | 2004-09-21 | 2006-03-23 | Woodward John R | Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
| JP5093998B2 (ja) | 2004-09-22 | 2012-12-12 | 大塚製薬株式会社 | 色素沈着予防又は改善剤 |
| DE102004046235A1 (de) | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| EP1811979B1 (de) | 2004-09-27 | 2008-11-05 | Sigmoid Pharma Limited | Mikrokapseln mit einem methylxanthin und einem kortikosteroid |
| US20060121016A1 (en) | 2004-10-18 | 2006-06-08 | Lee Raphael C | Methods and compositions for treatment of free radical injury |
| US20060120997A1 (en) | 2004-10-29 | 2006-06-08 | Biomune, Inc. | Cancer therapeutic compositions |
| EP1807452B1 (de) | 2004-11-02 | 2013-05-08 | DSM IP Assets B.V. | Additiv für uv-sonnenschutzzubereitungen |
| US8349359B2 (en) | 2004-11-07 | 2013-01-08 | Your Energy Systems, LLC | Liposomal formulation for oral administration of glutathione (reduced) |
| GB0424891D0 (en) | 2004-11-11 | 2004-12-15 | Boots Co Plc | Topical compositions |
| CA2587677C (en) | 2004-11-16 | 2013-05-28 | Bioavailability, Inc. | High concentration self-microemulsifying coenzyme q10 preparations for nutritional use |
| US20060110415A1 (en) | 2004-11-22 | 2006-05-25 | Bioderm Research | Topical Delivery System for Cosmetic and Pharmaceutical Agents |
| US20060127384A1 (en) | 2004-12-09 | 2006-06-15 | Sergio Capaccioli | Coenzyme Q10 as antiapoptotic agent |
| US7862995B2 (en) | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| WO2006063733A1 (en) | 2004-12-14 | 2006-06-22 | F.Hoffmann-La Roche Ag | Cd99 as target/marker for insulin resistance |
| WO2006063402A1 (en) | 2004-12-16 | 2006-06-22 | Melvin Mackenzie Stewart | Therapeutic compositions based on extracts of plants from the genus plumeria (frangipani) |
| NO20045674D0 (no) | 2004-12-28 | 2004-12-28 | Uni I Oslo | Thin films prepared with gas phase deposition technique |
| US20060286046A1 (en) | 2005-01-05 | 2006-12-21 | Haber C Andrew | Skin care compositions |
| US20060188492A1 (en) | 2005-01-13 | 2006-08-24 | Chronorx Llc, An Alaska Limited Liability Company | Topical management of ocular and periocular conditions |
| DE102005007980A1 (de) | 2005-02-22 | 2006-02-23 | Clariant Gmbh | Kosmetische, pharmazeutische oder dermatologische Zubereitungen enthaltend Copolymerwachse |
| JPWO2006103750A1 (ja) | 2005-03-29 | 2008-09-04 | 日本ハム株式会社 | 肥満改善用組成物、機能性食品及び医薬用組成物 |
| EP1871389A2 (de) | 2005-04-01 | 2008-01-02 | Zymes, LLC | Hautanreicherung mit coq10 als abgabesystem |
| CN1853507A (zh) | 2005-04-28 | 2006-11-01 | 尚宝虎 | 一种没有副作用的可用于饮料和固体口服制剂或食品添加的减肥新组方 |
| JP2007001922A (ja) | 2005-06-23 | 2007-01-11 | Asahi Kasei Pharma Kk | 透析患者における腎疾患改善剤、又は機能性食品 |
| US20070026072A1 (en) | 2005-07-28 | 2007-02-01 | Stephen Olsen | Benzoquinones of enhanced bioavailability |
| JPWO2007013556A1 (ja) * | 2005-07-28 | 2009-02-12 | 株式会社カネカ | 癌予防用組成物 |
| KR101562271B1 (ko) * | 2005-07-29 | 2015-10-21 | 티마 파운데이션 | 알콜대사를 완화하고 알콜유도성 질환의 위험을 감소하기위한 조성물 |
| US20070053985A1 (en) | 2005-08-24 | 2007-03-08 | Kaneka Corporation | Coenzyme Q10-containing fine particle with excellent dispersibility |
| CN1928556A (zh) | 2005-09-05 | 2007-03-14 | 中国医学科学院基础医学研究所 | 中国人2型糖尿病血清标志物的检测试剂盒 |
| US20070071779A1 (en) | 2005-09-26 | 2007-03-29 | Leggit Ingenuity, Llc | Compositions for delivering lipophilic agents to the intestinal mucosa and method of making thereof |
| EP1876448A1 (de) | 2005-09-30 | 2008-01-09 | DIGILAB BioVisioN GmbH | Verfahren und analytische Reagenzien zur Medikamentidentifizierung mittels auf Thiazolidinedionen reagierenden Biomarkern |
| US20070092469A1 (en) | 2005-10-26 | 2007-04-26 | Eric Jacobs | Topically applied Glucosamine Sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while PhosphatidylCholine is required to replace its deficiency caused by topical Dimethylaminoethanol (DMAE) |
| US8506956B2 (en) | 2005-10-31 | 2013-08-13 | Kaneka Corporation | Method for stabilizing reduced coenzyme Q10 |
| US9034316B2 (en) | 2006-10-24 | 2015-05-19 | Amorcyte, Llc | Infarct area perfusion-improving compositions and methods of vascular injury repair |
| US9265792B2 (en) | 2005-11-16 | 2016-02-23 | Patricia A. Riley | Integument cell regeneration formulation |
| CA2631236C (en) | 2005-12-01 | 2019-10-29 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| EP1957109A2 (de) | 2005-12-02 | 2008-08-20 | Sirtris Pharmaceuticals, Inc. | Modulatoren von cdc2-kinasen und verfahren zu ihrer verwendung |
| JP2007176804A (ja) | 2005-12-27 | 2007-07-12 | Ｚｍｃ−Ｋｏｕｇｅｎ株式会社 | 痩身作用を有する医薬又は健康食品 |
| US20070172436A1 (en) | 2006-01-23 | 2007-07-26 | Jerry Zhang | Nonaqueous ascorbic acid compositions and methods for preparing same |
| US20070184076A1 (en) | 2006-02-07 | 2007-08-09 | Unger Evan C | Liquid-filled nanodroplets for anti-cancer therapy |
| US20070184041A1 (en) | 2006-02-09 | 2007-08-09 | Burja Adam M | Methods and compositions related to production of coenzyme q10 |
| WO2007095186A2 (en) | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| US8067152B2 (en) | 2006-02-27 | 2011-11-29 | The Fred Hutchinson Cancer Research Center | Liver cancer biomarkers |
| US20070203091A1 (en) | 2006-02-28 | 2007-08-30 | Eliezer Rapaport | Methods and therapeutic compositions for improving liver, blood flow and skeletal muscle functions in advanced diseases and aging |
| CN101400337A (zh) | 2006-03-10 | 2009-04-01 | 拉伯斯威斯股份有限公司 | 物质的增溶、分散和稳定方法、由此方法制备的产品及其用途 |
| US7335384B2 (en) | 2006-03-17 | 2008-02-26 | 4K Nutripharma International | Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith |
| US8030013B2 (en) | 2006-04-14 | 2011-10-04 | Mount Sinai School Of Medicine | Methods and compositions for the diagnosis for early hepatocellular carcinoma |
| EP2017251B1 (de) | 2006-04-28 | 2017-07-19 | Kaneka Corporation | Verfahren zur stabilisierung von reduziertem coenzym q10 |
| JPWO2007126086A1 (ja) | 2006-04-28 | 2009-09-10 | 株式会社カネカ | 還元型補酵素ｑ１０の精製方法 |
| US8021659B2 (en) | 2006-04-28 | 2011-09-20 | Naidu Lp | Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof |
| EP3173068B1 (de) * | 2006-05-02 | 2020-09-09 | University of Miami | Topische co-enzym-q10-formulierungen und behandlung von wunden |
| WO2007142347A1 (ja) | 2006-06-05 | 2007-12-13 | Shimadzu Corporation | 腫瘍マーカー及び癌疾病の罹患の識別方法 |
| US20080020022A1 (en) | 2006-06-05 | 2008-01-24 | Udell Ronald G | Chewable co-enzyme q-10 capsule |
| US20080014187A1 (en) | 2006-07-15 | 2008-01-17 | Bryant Villeponteau | Compositions and Methods for Treating Hypertension and Inflammation |
| US8894993B2 (en) | 2006-08-04 | 2014-11-25 | Natreon Inc. | Mitochondria-targeted antioxidants |
| US7645616B2 (en) | 2006-10-20 | 2010-01-12 | The University Of Hong Kong | Use of lipocalin-2 as a diagnostic marker and therapeutic target |
| WO2008069276A1 (ja) | 2006-12-06 | 2008-06-12 | Kaneka Corporation | 癌治療剤および発癌抑制剤 |
| MX352434B (es) | 2007-03-22 | 2017-11-24 | Berg Llc | Formulaciones topicas que tienen biodisponibilidad aumentada. |
| US20090143279A1 (en) | 2007-06-15 | 2009-06-04 | Vamsi Krishna Mootha | Methods and compositions for treating metabolic disorders |
| US20090005398A1 (en) * | 2007-06-27 | 2009-01-01 | Mohammed Dar | Methods For The Treatment of Central Nervous System Tumors |
| US7989007B2 (en) | 2007-07-03 | 2011-08-02 | Vincent James Enterprises, Llc | Weight loss composition |
| KR100849537B1 (ko) | 2007-07-04 | 2008-07-31 | 유효경 | 코엔자임 큐텐의 나노에멀젼 조성물 |
| MX2010000414A (es) | 2007-07-17 | 2010-04-01 | Metabolon Inc | Biomarcadores para prediabetes, enfermedades cardiovasculares y otros trastornos relacionados con sindrome metabolico, y metodos de uso de los mismos. |
| CN101091890A (zh) | 2007-07-26 | 2007-12-26 | 沈阳药科大学 | 一种复合型乳化剂及用其制备的乳剂及其制备方法 |
| WO2009026163A1 (en) | 2007-08-17 | 2009-02-26 | Burnham Institute For Medical Research | Compositions and methods for inhibiting growth and metastasis of melanoma |
| RU2345367C1 (ru) | 2007-08-22 | 2009-01-27 | Государственное образовательное учреждение высшего профессионального образования Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО НГМУ Росздрава) | Способ прогнозирования тяжести течения и эффективности лечения лимфом |
| JP2009050168A (ja) | 2007-08-23 | 2009-03-12 | Tsujido Kagaku Kk | 食品組成物 |
| JP2010540498A (ja) | 2007-09-28 | 2010-12-24 | ウニヴェルズィテーツシュピタール バーゼル | 癌の治療のための免疫リポソーム |
| JP2009096757A (ja) | 2007-10-17 | 2009-05-07 | Tsujido Kagaku Kk | 脂肪代謝抑制剤 |
| EP2227085A4 (de) | 2007-12-06 | 2013-10-09 | Berg Pharma Llc | Inhalierbare zusammensetzungen mit gesteigerter biologischer verfügbarkeit |
| KR20100136997A (ko) | 2008-04-11 | 2010-12-29 | 싸이토테크 랩스, 엘엘씨 | 암세포에서 아폽토시스를 유도하는 방법 및 용도 |
| EP2307050A4 (de) | 2008-07-04 | 2012-07-25 | Ono Pharmaceutical Co | Verwendung eines wirksamkeitsmarkers zur optimierung der therapeutischen wirksamkeit eines antihuman-pd-1-ankörpers auf tumoren |
| DE102008060773A1 (de) | 2008-12-05 | 2010-06-10 | Sartorius Stedim Biotech Gmbh | Verschluss für einen Behälter |
| MX345044B (es) | 2009-05-11 | 2017-01-16 | Berg Llc | Métodos para el diagnóstico de trastornos oncológicos usando cambiadores epimetabólicos, moléculas intracelulares multidimensionales o influenciadores ambientales. |
| MX2012002208A (es) | 2009-08-25 | 2012-06-12 | Cytotech Labs Llc | Metodos para el tratamiento de un sarcoma empleando un cambiador epimetabolico (coenzima q10). |
| US8506954B2 (en) | 2009-12-01 | 2013-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Tumor vaccination in combination with hematopoietic cell transplantation for cancer therapy |
| EA032941B1 (ru) | 2010-03-12 | 2019-08-30 | БЕРГ ЭлЭлСи | ЛЕКАРСТВЕННЫЕ ФОРМЫ КОЭНЗИМА Q10 (CoQ10) ДЛЯ ВНУТРИВЕННОГО ВВЕДЕНИЯ И ИХ ПРИМЕНЕНИЕ |
| KR101917975B1 (ko) | 2010-07-19 | 2018-11-13 | 바이오젠 체사피크 엘엘씨 | 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법 |
| US9125835B2 (en) | 2010-11-12 | 2015-09-08 | Rutgers, The State University Of New Jersey | Synergistic combinations to reduce particle dose for targeted treatment of cancer and its metastases |
| EP2694463B8 (de) | 2011-04-04 | 2019-10-09 | Berg LLC | Behandlung von tumoren im zentralnervensystem mit coenzym q10 |
| SG11201407880QA (en) | 2012-06-01 | 2014-12-30 | Berg Llc | Treatment of solid tumors using coenzyme q10 |
| EP2983654A4 (de) | 2013-04-08 | 2016-11-30 | Berg Llc | Behandlung von krebs mit coenzym-q10-kombinationstherapien |
| KR102370843B1 (ko) | 2013-09-04 | 2022-03-04 | 버그 엘엘씨 | 코엔자임 q10의 연속주입에 의한 암치료 방법 |
| JP6398212B2 (ja) | 2014-02-12 | 2018-10-03 | 株式会社Ihi | 軸受構造、および、過給機 |
| KR20170063722A (ko) | 2014-10-03 | 2017-06-08 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 선천적 면역 반응의 종양 유도된 면역억제를 차단하기 위한 방법으로서의 아넥신 v의 사용 |
| US20190194654A1 (en) | 2014-10-24 | 2019-06-27 | Astrazeneca Ab | Combination |
| US9827308B2 (en) | 2014-12-10 | 2017-11-28 | Wisconsin Alumni Research Foundation | Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade |
| US20170189350A1 (en) | 2015-11-16 | 2017-07-06 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| US20180021270A1 (en) | 2016-07-21 | 2018-01-25 | Berg Llc | Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators |
| JP6895250B2 (ja) | 2016-12-28 | 2021-06-30 | 日東電工株式会社 | 表面保護フィルム |
| US20200138744A1 (en) | 2018-10-15 | 2020-05-07 | Berg Llc | Methods of treating pancreatic cancer using coenzyme q10 |
-
2012
- 2012-04-04 EP EP12767439.8A patent/EP2694463B8/de active Active
- 2012-04-04 US US13/439,615 patent/US20120269867A1/en not_active Abandoned
- 2012-04-04 KR KR1020137028856A patent/KR101933732B1/ko active Active
- 2012-04-04 WO PCT/US2012/032178 patent/WO2012138765A1/en active Application Filing
- 2012-04-04 CN CN201280027222.1A patent/CN103608323B/zh active Active
- 2012-04-04 CA CA2832324A patent/CA2832324C/en active Active
- 2012-04-04 ES ES12767439T patent/ES2762451T3/es active Active
- 2012-04-04 JP JP2014503955A patent/JP6092844B2/ja active Active
- 2012-04-04 AU AU2012240222A patent/AU2012240222B2/en active Active
-
2016
- 2016-12-12 US US15/376,243 patent/US10376477B2/en active Active
-
2017
- 2017-02-09 JP JP2017022188A patent/JP6262894B2/ja not_active Expired - Fee Related
- 2017-07-21 AU AU2017206279A patent/AU2017206279B2/en not_active Ceased
- 2017-12-14 JP JP2017239481A patent/JP6427256B2/ja active Active
-
2019
- 2019-06-18 US US16/444,296 patent/US11452699B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6262894B2 (ja) | 2018-01-17 |
| US20200078320A1 (en) | 2020-03-12 |
| EP2694463B1 (de) | 2019-09-04 |
| CA2832324C (en) | 2022-03-15 |
| AU2012240222B2 (en) | 2017-04-27 |
| EP2694463A4 (de) | 2014-10-29 |
| JP2014510144A (ja) | 2014-04-24 |
| AU2012240222A8 (en) | 2013-11-14 |
| ES2762451T3 (es) | 2020-05-25 |
| CN103608323A (zh) | 2014-02-26 |
| JP2017110027A (ja) | 2017-06-22 |
| US11452699B2 (en) | 2022-09-27 |
| CN103608323B (zh) | 2016-08-17 |
| US10376477B2 (en) | 2019-08-13 |
| US20120269867A1 (en) | 2012-10-25 |
| CA2832324A1 (en) | 2012-10-11 |
| AU2017206279B2 (en) | 2019-08-15 |
| KR20140026448A (ko) | 2014-03-05 |
| AU2017206279A1 (en) | 2017-08-10 |
| AU2012240222A1 (en) | 2013-10-24 |
| JP2018065853A (ja) | 2018-04-26 |
| US20170246125A1 (en) | 2017-08-31 |
| WO2012138765A1 (en) | 2012-10-11 |
| KR101933732B1 (ko) | 2018-12-28 |
| EP2694463A1 (de) | 2014-02-12 |
| JP6427256B2 (ja) | 2018-11-21 |
| JP6092844B2 (ja) | 2017-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2694463B8 (de) | Behandlung von tumoren im zentralnervensystem mit coenzym q10 | |
| AP4010A (en) | Belt allignment system with rotatable bushing | |
| EP2854528B8 (de) | Behandlung von festen tumoren mittels des coenzyms q10 | |
| IL260077A (en) | Methods of treating excess bilirubin in the blood with stanoporfin | |
| ZA201403764B (en) | Dual cure system | |
| HK1179823A1 (en) | Methods for treating methotrexate-resistant disorders with 10-propargyl-10- deazaaminopterin 10--10- | |
| SI2729810T1 (sl) | Miozitis | |
| WO2013130150A9 (en) | Metalloporphyrin neurological treatments | |
| WO2012106368A9 (en) | Methods for inhibiting prostate cancer | |
| AU2011905110A0 (en) | Trolley Seat | |
| AU2011904279A0 (en) | Combination Therapy | |
| AU2011902623A0 (en) | Combination therapy | |
| AU2011900060A0 (en) | Combination Therapy | |
| AU2011905430A0 (en) | Heating System | |
| AU2012901918A0 (en) | Methods for treating cancer | |
| AU2011901160A0 (en) | Magnetic therapy headwear | |
| AU2012905368A0 (en) | Dual fuel supply | |
| PH32011000251S1 (en) | Inline dimmer | |
| AU2011904905A0 (en) | Wheel retention system | |
| AU2012901283A0 (en) | Magnetic therapy headwear | |
| AU2011900737A0 (en) | Methods of Treating a Disease or Condition of the Central Nervous System | |
| AU2011904865A0 (en) | Trolley | |
| AU2011902841A0 (en) | Trolley | |
| AU2011900000A0 (en) | Worksafe trolley | |
| AU2011902737A0 (en) | Carrier |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20131104 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1194361 Country of ref document: HK |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20140930 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/02 20060101ALI20140924BHEP Ipc: A61P 35/00 20060101ALI20140924BHEP Ipc: A61K 31/122 20060101AFI20140924BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20170929 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20190415 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: PK Free format text: BERICHTIGUNG B8 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1174363 Country of ref document: AT Kind code of ref document: T Effective date: 20190915 |
|
| RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: BERG LLC |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012063657 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20190904 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191204 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191204 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191205 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1174363 Country of ref document: AT Kind code of ref document: T Effective date: 20190904 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200106 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2762451 Country of ref document: ES Kind code of ref document: T3 Effective date: 20200525 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200224 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012063657 Country of ref document: DE |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG2D | Information on lapse in contracting state deleted |
Ref country code: IS |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200105 |
|
| 26N | No opposition filed |
Effective date: 20200605 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200430 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200404 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200430 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20200430 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200430 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200404 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230529 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20241031 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20241015 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20241015 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20241017 Year of fee payment: 13 Ref country code: ES Payment date: 20241104 Year of fee payment: 13 |